GlassScriptPhysician profile
Rokeya Tasnin
NPI 1285820001
$15,033.83
in general payments reported to CMS, 2019-2025
31 companies · $6,331 in 2025
The $6,331 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $546 · 2021: $806 · 2022: $1,666 · 2023: $2,236 · 2024: $2,537 · 2025: $6,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $27.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,075.44 |
| Education | $27.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,950.60 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,543.67 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,543.03 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $1,502.11 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $1,339.61 | 2019-2025 | Fanapt, Hetlioz, Ponvory |
| Alkermes, INC. | $1,255.06 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,249.12 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $811.86 | 2019-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $774.27 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $734.47 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $395.62 | 2019-2025 | Ingrezza |
| Tris Pharma INC | $314.59 | 2023-2025 | Dyanavel Xr, Quillichew Er |
| Supernus Pharmaceuticals, INC. | $254.39 | 2024-2025 | Qelbree |
| Corium, LLC | $238.08 | 2021-2024 | Azstarys |
| Indivior INC. | $231.99 | 2020-2025 | Perseris, Sublocade |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $213.89 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $146.07 | 2019-2024 | Jornay Pm |
| Almatica Pharma LLC | $139.98 | 2022-2025 | Loreev Xr, Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $99.44 | 2019-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $42.31 | 2021 | |
| Shire North American Group INC | $38.52 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34.91 | 2024-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $29.66 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $27.81 | 2019-2020 | |
| Biogen, INC. | $24.99 | 2025 | Zurzuvae |
| Sage Therapeutics, LLC | $22.98 | 2025 | Zurzuvae |
| Avanir Pharmaceuticals, INC. | $16.83 | 2022 | |
| Braeburn INC. | $16.42 | 2023 | Brixadi |
| Luye Pharma (USA) LTD. | $14.83 | 2025 | Erzofri Extended-Release |
| Merck Sharp & Dohme LLC | $13.76 | 2022 | |
| Allergan, INC. | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rokeya Tasnin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.